These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33312457)

  • 1. The impact of patent expiry on drug prices: insights from the Dutch market.
    van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH
    J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457
    [No Abstract]   [Full Text] [Related]  

  • 2. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
    Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
    Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.
    Serra-Burriel M; Martin-Bassols N; Perényi G; Vokinger KN
    JAMA Health Forum; 2024 Aug; 5(8):e242530. PubMed ID: 39150730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
    Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
    BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
    Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ
    Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of price competition in Italian pharmaceutical off-patent market.
    Perna S; Cangini A; Marini R; Guerrizio MA; Da Cas R; Traversa G; Trotta F
    Front Med (Lausanne); 2022; 9():1045374. PubMed ID: 36523775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.
    Heath K
    Clinicoecon Outcomes Res; 2018; 10():539-550. PubMed ID: 30288069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing dynamics of anti-seizure medications in the U.S.
    Javarayee P; Mtchedlidze T; Snell W; Mahesha V; Meylor J; Shahrukh S; Pollock S; Sah J; Dong Y; Patel H
    Seizure; 2024 Nov; 122():26-33. PubMed ID: 39306895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Competition on Generic Drug Prices.
    Nguyen NX; Sheingold SH; Tarazi W; Bosworth A
    Appl Health Econ Health Policy; 2022 Mar; 20(2):243-253. PubMed ID: 34904207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.
    Kanavos P
    Health Policy; 2014 Nov; 118(2):229-41. PubMed ID: 25201433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Patent Expiry on the Performance of Innovator Multinational Pharmaceutical Companies in a Low Middle Income Country.
    Khalil F; Onyango JO
    Front Med Technol; 2022; 4():783460. PubMed ID: 35445207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
    Boonen LH; van der Geest SA; Schut FT; Varkevisser M
    Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV care cost in England: a cross-sectional analysis of antiretroviral treatment and the impact of generic introduction.
    Ong KJ; van Hoek AJ; Harris RJ; Figueroa J; Waters L; Chau C; Croxford S; Kirwan P; Brown A; Postma MJ; Gill ON; Delpech V
    HIV Med; 2019 Jul; 20(6):377-391. PubMed ID: 31034159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
    Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
    Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.